查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1574220

克隆氏症药物市场：按药物类别、给药途径、分销管道、年龄层划分 - 全球预测 2025-2030

Crohn's Disease Therapeutics Market by Therapeutics Class (Biologics, Conventional Drugs), Route Of Administration (Oral, Parenteral), Distribution Channel, Age Group - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

克隆氏症治疗药物市场2023年估值为127.6亿美元，预计到2024年将达到133.6亿美元，复合年增长率为5.47%，预计到2030年将达到185.4亿美元。

克隆氏症药物的范围和定义包括各种旨在控制症状、诱导和维持缓解以及改善这种慢性发炎性肠道疾病患者的生活品质的治疗方法。由于克隆氏症，需要这些治疗，这种疾病会导致腹痛、严重腹泻、疲劳和营养不良等衰弱症状。治疗应用范围从发炎药物和免疫抑制剂到生技药品和新的个人化医疗方法。最终用途范围主要是医疗保健环境，例如医院、专科诊所和专注于胃肠道疾病的研究机构。影响市场成长的关键因素包括生物製药治疗的进步、克隆氏症全球盛行率的增加以及患者和医疗保健专业人员对新治疗方案的认识不断提高。然而，他们面临着治疗成本上升、潜在副作用以及患者对治疗反应不同等挑战。最新的潜在治疗机会来自肠道微生物组治疗和个人化医疗的持续研究，提供有针对性的有效治疗方法。建议的治疗方法包括投资新治疗方法的研发、利用资料分析制定个人化治疗计划以及建立策略伙伴关係以扩大市场。监管障碍和生物相似药的竞争压力等限制仍然是主要挑战。最佳创新领域是生物相似药的开发、预测诊断基因研究的进展以及使用数位健康技术进行患者监测和参与。该市场的特点是技术快速进步，但必须谨慎管理监管环境和成本管理，以确保永续成长。透过专注于云端基础的研究合作和以患者为中心的护理模式，公司可以对自己进行策略性定位，以利用市场的动态特性。

主要市场统计
基准年[2023] 127.6亿美元
预测年份 [2024] 133.6亿美元
预测年份 [2030] 185.4亿美元
复合年增长率（%） 5.47%

市场动态：揭示快速发展的克隆氏症症药物市场的关键市场洞察

克隆氏症药物市场正在因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 由于患者预后改善，对克隆氏症标靶治疗的需求增加
    • 扩大发展中地区克隆氏症治疗的医疗基础设施和可近性
    • 支持克隆氏症研究和开发新药的政府措施和资金
    • 生物创业公司与研究机构联合研究开发新药
  • 市场限制因素
    • 严格的监管要求推迟了克隆氏症病药物的核准
    • 缺乏可靠的临床试验资料削弱了人们对克隆氏症药物的信心
  • 市场机会
    • 开发永续且具成本效益的生物製药，用于克隆氏症的长期管理
    • 探索肠道菌丛调整疗法在克隆氏症治疗的潜力
    • 扩大精准医学的使用，以确定个别患者对克隆氏症治疗的反应
  • 市场挑战
    • 解决患者对克隆氏症治疗方法的依从性和长期承诺
    • 解决与先进克隆氏症治疗相关的高成本和保险障碍

波特五力：驾驭克隆氏症药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解克隆氏症药物市场的外部影响

外部宏观环境因素在塑造克隆氏症治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解克隆氏症治疗药物市场的竞争状况

对克隆氏症治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来发现自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵克隆氏症治疗市场供应商的绩效评估

FPNV 定位矩阵是评估克隆氏症治疗市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划克隆氏症治疗药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对克隆氏症治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 患者治疗效果的改善推动了克隆氏症标靶治疗的需求
      • 扩大发展中地区克隆氏症治疗的医疗基础设施和可近性
      • 支持克隆氏症研究和开发新药的政府措施和资金
      • 生技公司与研究机构合作开发新的克隆氏症治疗方法
    • 抑制因素
      • 严格的监管要求推迟了克隆氏症新疗法的核准
      • 缺乏可靠的临床试验资料降低了人们对克隆氏症药物的信心
    • 机会
      • 开发永续且具有成本效益的生物治疗方法来长期管理克隆氏症
      • 探索肠道微生物群调节疗法治疗克隆氏症的潜力
      • 扩大精准医学的使用以确定个别患者对克隆氏症治疗的反应
    • 任务
      • 解决患者对克隆氏症治疗方法的依从性和长期承诺
      • 管理与晚期克隆氏症治疗相关的高成本和保险障碍
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗层级的克隆氏症治疗药物市场

  • 生物製药
    • 抗整合素治疗
    • 白细胞介素抑制剂
    • 单株抗体
  • 传统医学
    • 氨基胺基
    • 皮质类固醇
    • 免疫抑制剂

第七章克隆氏症治疗药物市场：依给药途径

  • 口服
    • 胶囊
    • 药片
  • 胃肠外的
    • 注射

第八章克隆氏症治疗药物市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第九章克隆氏症治疗药物市场：依年龄组

  • 成人
  • 小儿科

第十章美洲克隆氏症药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太克隆氏症药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲克隆氏症药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064C0471

The Crohn's Disease Therapeutics Market was valued at USD 12.76 billion in 2023, expected to reach USD 13.36 billion in 2024, and is projected to grow at a CAGR of 5.47%, to USD 18.54 billion by 2030.

The scope and definition of Crohn's Disease Therapeutics encompass the various treatments aimed at managing symptoms, inducing and maintaining remission, and improving the quality of life for patients suffering from this chronic inflammatory bowel disease. The necessity for these therapeutics is driven by the complex nature of Crohn's Disease, which can lead to debilitating symptoms such as abdominal pain, severe diarrhea, fatigue, and malnutrition. The application of therapeutics ranges from anti-inflammatory drugs and immunosuppressants to biologics and emerging personalized medicine approaches. End-use scope is primarily in healthcare settings such as hospitals, specialist clinics, and research institutions focusing on gastrointestinal disorders. Key factors influencing market growth include advancements in biologic therapies, increasing prevalence of Crohn's Disease globally, and rising awareness among patients and healthcare providers about new treatment options. However, the market faces challenges due to high treatment costs, potential side effects, and varying patient responses to therapies. Latest potential opportunities arise from ongoing research in gut microbiome therapies and personalized medicine, offering targeted and efficient treatment practices. Recommendations include investing in R&D for novel therapies, leveraging data analytics for personalized treatment plans, and engaging in strategic partnerships to expand market reach. Limitations such as regulatory hurdles and competitive pressure from biosimilars remain significant challenges. The best areas of innovation lie in the development of biosimilars, advancements in genetic studies for predictive diagnostics, and leveraging digital health technologies for patient monitoring and engagement. The market is characterized by rapid technological advancements but requires careful navigation through regulatory landscapes and cost management to ensure sustainable growth. By focusing on cloud-based research collaborations and patient-centric care models, businesses can strategically position themselves to leverage the dynamic nature of the Crohn's Disease Therapeutics market.

KEY MARKET STATISTICS
Base Year [2023] USD 12.76 billion
Estimated Year [2024] USD 13.36 billion
Forecast Year [2030] USD 18.54 billion
CAGR (%) 5.47%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Crohn's Disease Therapeutics Market

The Crohn's Disease Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing demand for targeted Crohn's disease treatments due to better patient outcomes
    • Expanded healthcare infrastructure and accessibility in developing regions for Crohn's disease treatment
    • Government initiatives and funding to support Crohn's disease research and new drug development
    • Collaborations between biotech firms and research institutions for novel Crohn's disease therapeutics
  • Market Restraints
    • Stringent regulatory requirements slow down the approval of new Crohn's disease treatments
    • Lack of robust clinical trial data diminishes confidence in Crohn's disease therapeutics
  • Market Opportunities
    • Developing sustainable and cost-effective biologic therapies for long-term management of Crohn's disease
    • Exploring the potential of gut microbiome modulation therapies in the treatment of Crohn's disease
    • Expanding the use of precision medicine in identifying individual patient response to Crohn's disease treatments
  • Market Challenges
    • Addressing patient adherence and long-term commitment to Crohn's disease therapeutic regimens
    • Managing high costs and insurance barriers associated with advanced Crohn's disease treatments

Porter's Five Forces: A Strategic Tool for Navigating the Crohn's Disease Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Crohn's Disease Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Crohn's Disease Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Crohn's Disease Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Crohn's Disease Therapeutics Market

A detailed market share analysis in the Crohn's Disease Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Crohn's Disease Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Crohn's Disease Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Crohn's Disease Therapeutics Market

A strategic analysis of the Crohn's Disease Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Crohn's Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Ferring Pharmaceuticals Inc., Gilead Sciences Inc., Ipsen Biopharmaceuticals, Inc., Johnson & Johnson, Merck & Co., Inc., Nestle Health Science, Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi S.A., Shire plc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Crohn's Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutics Class, market is studied across Biologics and Conventional Drugs. The Biologics is further studied across Anti-Integrin Therapy, Interleukin Inhibitors, and Monoclonal Antibodies. The Conventional Drugs is further studied across Aminosalicylates, Corticosteroids, and Immunosuppressants.
  • Based on Route Of Administration, market is studied across Oral and Parenteral. The Oral is further studied across Capsules and Tablets. The Parenteral is further studied across Injectables.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Age Group, market is studied across Adults and Pediatric.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing demand for targeted Crohn's disease treatments due to better patient outcomes
      • 5.1.1.2. Expanded healthcare infrastructure and accessibility in developing regions for Crohn's disease treatment
      • 5.1.1.3. Government initiatives and funding to support Crohn's disease research and new drug development
      • 5.1.1.4. Collaborations between biotech firms and research institutions for novel Crohn's disease therapeutics
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulatory requirements slow down the approval of new Crohn's disease treatments
      • 5.1.2.2. Lack of robust clinical trial data diminishes confidence in Crohn's disease therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Developing sustainable and cost-effective biologic therapies for long-term management of Crohn's disease
      • 5.1.3.2. Exploring the potential of gut microbiome modulation therapies in the treatment of Crohn's disease
      • 5.1.3.3. Expanding the use of precision medicine in identifying individual patient response to Crohn's disease treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Addressing patient adherence and long-term commitment to Crohn's disease therapeutic regimens
      • 5.1.4.2. Managing high costs and insurance barriers associated with advanced Crohn's disease treatments
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Crohn's Disease Therapeutics Market, by Therapeutics Class

  • 6.1. Introduction
  • 6.2. Biologics
    • 6.2.1. Anti-Integrin Therapy
    • 6.2.2. Interleukin Inhibitors
    • 6.2.3. Monoclonal Antibodies
  • 6.3. Conventional Drugs
    • 6.3.1. Aminosalicylates
    • 6.3.2. Corticosteroids
    • 6.3.3. Immunosuppressants

7. Crohn's Disease Therapeutics Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Oral
    • 7.2.1. Capsules
    • 7.2.2. Tablets
  • 7.3. Parenteral
    • 7.3.1. Injectables

8. Crohn's Disease Therapeutics Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Crohn's Disease Therapeutics Market, by Age Group

  • 9.1. Introduction
  • 9.2. Adults
  • 9.3. Pediatric

10. Americas Crohn's Disease Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Crohn's Disease Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Crohn's Disease Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Biogen Inc.
  • 4. Bristol-Myers Squibb Company
  • 5. Celgene Corporation
  • 6. Eli Lilly and Company
  • 7. Ferring Pharmaceuticals Inc.
  • 8. Gilead Sciences Inc.
  • 9. Ipsen Biopharmaceuticals, Inc.
  • 10. Johnson & Johnson
  • 11. Merck & Co., Inc.
  • 12. Nestle Health Science
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Roche Holding AG
  • 16. Sanofi S.A.
  • 17. Shire plc.
  • 18. Takeda Pharmaceutical Company Limited
  • 19. Teva Pharmaceutical Industries Ltd.
  • 20. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. CROHN'S DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CROHN'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CROHN'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CROHN'S DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CROHN'S DISEASE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTI-INTEGRIN THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 98. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 105. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 106. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 110. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 111. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 113. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 114. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 116. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 118. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 119. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 121. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 122. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 124. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 126. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 127. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 129. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 130. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 132. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 134. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 135. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 137. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 138. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 140. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 142. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 143. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 145. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 146. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 148. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 149. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 150. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 151. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 153. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 154. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 156. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 157. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 158. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 164. TAIWAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 165. TAIWAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 166. TAIWAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 167. TAIWAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. TAIWAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 169. TAIWAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 170. TAIWAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 172. THAILAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 173. THAILAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 174. THAILAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 175. THAILAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. THAILAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 177. THAILAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 178. THAILAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 180. VIETNAM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 181. VIETNAM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 182. VIETNAM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 183. VIETNAM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. VIETNAM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 185. VIETNAM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 186. VIETNAM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 197. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 198. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 199. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 200. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 201. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 202. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 203. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 205. EGYPT CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 206. EGYPT CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 207. EGYPT CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 208. EGYPT CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. EGYPT CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 210. EGYPT CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 211. EGYPT CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 213. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 214. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 215. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 216. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 218. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 219. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 221. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 222. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 223. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 224. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 225. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 226. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 227. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 229. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 230. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 231. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 232. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 234. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 235. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 237. ISRAEL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 238. ISRAEL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 239. ISRAEL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 240. ISRAEL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 241. ISRAEL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 242. ISRAEL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 243. ISRAEL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 245. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 246. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 247. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 248. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 249. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 250. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 251. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 252. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 253. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 254. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 255. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 256. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 257. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 258. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 259. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 261. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 262. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 263. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 264. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 265. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 266. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 267. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 269. NORWAY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 270. NORWAY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 271. NORWAY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 272. NORWAY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 273. NORWAY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 274. NORWAY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 275. NORWAY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 277. POLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 278. POLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 279. POLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 280. POLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 281. POLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 282. POLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 283. POLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 284. POLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 285. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 286. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 287. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 288. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 289. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 290. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 291. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 292. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 293. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 294. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 295. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 296. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 297. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 298. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 299. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 300. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 301. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 302. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 303. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 304. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 305. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 306. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 307. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 308. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 309. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 310. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 311. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 312. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 313. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 314.